TXA127 300 mcg/kg/day + TXA127 1000 mcg/kg/day
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Double Cord Blood Transplant
Conditions
Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Myelofibrosis, Acute Lymphoblastic Leukemia, Chronic Myelocytic Leukemia, Non Hodgkins Lymphoma, Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Trial Timeline
Jan 1, 2011 → Dec 1, 2020
NCT ID
NCT01300611About TXA127 300 mcg/kg/day + TXA127 1000 mcg/kg/day
TXA127 300 mcg/kg/day + TXA127 1000 mcg/kg/day is a phase 1 stage product being developed by Constant Therapeutics for Double Cord Blood Transplant. The current trial status is terminated. This product is registered under clinical trial identifier NCT01300611. Target conditions include Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01300611 | Phase 1 | Terminated |
Competing Products
2 competing products in Double Cord Blood Transplant
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Brincidofovir | Jazz Pharmaceuticals | Phase 3 | 74 |
| Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab Tesirine + Prednisone + Rituximab + Vincristine | ADC Therapeutics | Phase 2 | 44 |